logo
NGOs barred from donating food at premises of Government General Hospital in Guntur

NGOs barred from donating food at premises of Government General Hospital in Guntur

Time of India18-05-2025

1
2
3
Guntur: The hospital development society (HDS) of Government General Hospital (GGH) in Guntur has made a decision that has left many in shock. The society has decided not to allow private individuals and non-governmental organizations (NGOs) to organize
food donation camps
within the hospital premises, citing sanitation issues as the reason.
This decision has been met with widespread criticism, with many questioning the logic behind it. The HDS has instead decided to collect additional charges from NGOs if they still want to donate food to the poor, including the families of patients. This move is being seen as a deterrent to charity organizations and NGOs that have been providing essential services to the needy.
The GGH provides free food to patients and one attendant, but the reality is that each patient is usually accompanied by at least two to three attendants, most of whom come from far-off places.
These attendants often rely on private canteens or food donation camps for their meals. In the past, charity organizations and NGOs have played a vital role in providing food to these attendants.
One such initiative was the Madhurannam canteen, which was set up by former minister Cherukuvada Rangantha Raju of YSRCP. The canteen provides sumptuous food to around 1,000 to 1,500 people per day. However, despite such initiatives, hundreds of people still wait for charity organizations to visit the GGH and distribute food packets.
The decision to ban charity organizations from entering the hospital has been met with strong opposition. A social activist, K Rajendraprasad, has expressed his outrage, stating that the GGH should deploy additional sanitation workers to keep the food distribution areas clean instead of banning charity organizations.
In a related development, the HDS has also resolved to suspend its request for setting up an Anna canteen in the hospital.
This decision has been met with disappointment, as the Anna canteen would have provided much-needed relief to thousands of poor people.
The contrast between the GGH's decision and the agriculture market yard's initiative to set up a free food canteen is stark. The market yard spends over Rs 50 lakh per year to feed farmers, despite having an Anna canteen nearby. The GGH's decision to prioritize sanitation concerns over the needs of the poor has left many questioning its priorities.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

eYantra Ventures Ltd concludes board meeting to declare audited financial results for FY 2024-25
eYantra Ventures Ltd concludes board meeting to declare audited financial results for FY 2024-25

Business Standard

timean hour ago

  • Business Standard

eYantra Ventures Ltd concludes board meeting to declare audited financial results for FY 2024-25

VMPL Hyderabad (Telangana) [India], June 11: eYantra Ventures Ltd (BSE: 512099), reported its standalone and consolidated financial results according to Ind AS for the quarter and financial year (FY) ending March 31, 2025. Consolidated revenue grew by 95% at Rs. 32.89 Crores during FY 2024-25, led by performance both the business divisions of the company i.e. Merchandising and IT Services. The Board of Directors, in its meeting held on 30th May 2025, approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March 2025. Strong Group-Wide Business Performance The consolidated operations of eYantra Group which includes eYantra Ventures Ltd, Prismberry Technologies Pvt. Ltd, eYantra Ventures FZE (UAE) achieved a total business turnover of Rs. 32.89 Crores in FY 2024-25, a remarkable 95% growth over the previous year's Rs. 16 Crores. This growth reflects the Group's multi-sector presence spanning B2B merchandise and IT services. eYantra group has business operations in multiple cities across India and other geographies including UAE and USA. During FY2025, eYantra Ventures Ltd invested in Neuro and Spine Associates Pvt Ltd (NASA) by securing a 38.65% equity stake as of 31st March 2025. Focused on neurosciences, spine care and orthopaedics, NASA operates in a high-potential segment within India's healthcare landscape. In line with Indian Accounting Standards (IND-AS 28), the investment is being accounted for as an associate and therefore is not consolidated under IND-AS 110 for the FY 2024-25. NASA currently has 2 hospitals in Hyderabad and Vijayawada with a combined capacity of 180 beds. During FY 2024-25 the company raised Rs. 15 crores through private placement by way of preferential issue of equity shares to fund various objectives including working capital requirements & pursuing strategic investments.

Energy Minister Gottipati inaugurates Urban Primary Health Centre in Addanki segment
Energy Minister Gottipati inaugurates Urban Primary Health Centre in Addanki segment

New Indian Express

timean hour ago

  • New Indian Express

Energy Minister Gottipati inaugurates Urban Primary Health Centre in Addanki segment

GUNTUR: Energy Minister Gottipati Ravi Kumar, accompanied by Bapatla District Collector J Venkata Murali, inaugurated a newly constructed Urban Primary Health Centre in Addanki town on Tuesday. Built at a cost of Rs 1.5 crore, the facility is part of the NDA government's ongoing efforts to enhance healthcare services for economically weaker sections. Addressing the gathering, Ravi said the government, under the leadership of Chief Minister N Chandrababu Naidu, has sanctioned five health centres in the Addanki segment. While the new centre is operational, four more are expected to open by the end of the month. He announced plans to set up a dialysis centre in Medarametla to address the healthcare needs of the locals. He opened a newly laid Rs 1.2 crore tar road from Naam Road to Govada village. He said Rs 6 crore worth of road works were completed in Phase I, with Rs 7.5 crore under Phase II.

Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane
Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane

Business Standard

time3 hours ago

  • Business Standard

Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane

Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets. Xbrane Biopharma AB is a biotechnology company. It develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSources integrated drug substance and drug product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbranes global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbranes latest funding round, reinforcing the long-term alignment between the two companies. Neeraj Sharma, managing director & CEO of OneSource Specialty Pharma, said: The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbranes proven success in biosimilar development, combined with OneSources fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the worlds leading biotech companies. OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. On a consolidated basis, OneSource Specialty Pharma reported net profit of Rs 98.50 crore in Q4 March 2025 as against net loss of Rs 40.17 crore in Q4 March 2024. Net sales surged 482.38% YoY to Rs 425.95 crore in Q4 March 2025.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store